

DAFTAR PUSTAKA

1. Permono B, Ugrasena I. Leukemia Akut. In: Pramono B, Sutaryo, Ugrasena I, Windiastuti E, Abdulsalam M, editors. Buku Ajar Hematologi-Onkologi Anak. Jakarta: Badan Penerbit IDAI; 2005. h. 236-47.
2. Behrman RE, Kliegman R, Nelson WE. Infection in the Immunocompromised. Nelson Essentials of Pediatrics. 5th ed. Philadelphia: W.B. Saunders; 2006. h. 958-67.
3. Morris PG, Hassan T, McNamara M, Hassan A, Wiig R, Grogan L, et al. Emergence of Mrsa in Positive Blood Cultures from Patients with Febrile Neutropenia--a Cause for Concern. Support Care Cancer. 2008; 16(9):1085-8.
4. Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J. Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated with 3-4 Week Chemotherapy Regimens in Community Oncology Practices. J Manag Care Pharm. 2007; 13(4):337-48.
5. Yuniastuti. Evaluasi Penggunaan Antibiotika Pada Pasien Keganasan Hematologi Dengan Febrile Neutropenia Setelah Pemberian Kemoterapi Di Rs Kanker Dharmais Jakarta Periode Januari 2002-September 2003 [Thesis Abstract]. Yogyakarta: Gadjah Mada University; 2004.
6. Gunawan S, Rampengan NH, Mantik M, Rampengan TH. Factors Correlated with Febrile Neutropenia and the Outcome in Children with Cancer: Manado Experience 1997 - 2006. J Ped Infect Dis. 2008; 4:163-9.
7. Bosnjak S. Treatment of a Febrile Neutropenic Patient. Arch Oncol. [symposium article]. 2004; 12(3):179-81.
8. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, et al. 1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever. Infectious Diseases Society of America. Clin Infect Dis. 1997; 25(3):551-73.
9. Mendes AV, Sapolnik R, Mendonca N. New Guidelines for the Clinical Management of Febrile Neutropenia and Sepsis in Pediatric Oncology Patients. J Pediatr (Rio J). 2007; 83(2 Suppl):S54-63.
10. Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the Management of Febrile Neutropenic Patients with Cancer in the 21st Century. Cancer. 2005; 103(6):1103-13.
11. Viscoli C, Varnier O, Machetti M. Infections in Patients with Febrile Neutropenia: Epidemiology, Microbiology, and Risk Stratification. Clin Infect Dis. 2005; 40 Suppl 4:S240-5.
12. Lyman GH, Lyman CH, Agboola O. Risk Models for Predicting Chemotherapy-Induced Neutropenia. Oncologist. 2005; 10(6):427-37.
13. Santolaya ME, Alvarez AM, Becker A, Cofre J, Enriquez N, O'Ryan M, et al. Prospective, Multicenter Evaluation of Risk Factors Associated with

- Invasive Bacterial Infection in Children with Cancer, Neutropenia, and Fever. *J Clin Oncol*. 2001; 19(14):3415-21.
14. Alexandre J, Gross-Goupil M, Falissard B, Nguyen ML, Gornet JM, Misset JL, et al. Evaluation of the Nutritional and Inflammatory Status in Cancer Patients for the Risk Assessment of Severe Haematological Toxicity Following Chemotherapy. *Ann Oncol*. 2003; 14(1):36-41.
 15. Paganini HR, Aguirre C, Puppa G, Garbini C, Javier RG, Ensinnck G, et al. A Prospective, Multicentric Scoring System to Predict Mortality in Febrile Neutropenic Children with Cancer. *Cancer*. 2007; 109(12):2572-9.
 16. Voog E, Bienvenu J, Warzocha K, Moullet I, Dumontet C, Thieblemont C, et al. Factors That Predict Chemotherapy-Induced Myelosuppression in Lymphoma Patients: Role of the Tumor Necrosis Factor Ligand-Receptor System. *J Clin Oncol*. 2000; 18(2):325-31.
 17. Santolaya ME, Alvarez AM, Aviles CL, Becker A, Cofre J, Cumsille MA, et al. Early Hospital Discharge Followed by Outpatient Management Versus Continued Hospitalization of Children with Cancer, Fever, and Neutropenia at Low Risk for Invasive Bacterial Infection. *J Clin Oncol*. 2004; 22(18):3784-9.
 18. Intragumtornchai T, Sutheesophon J, Sutcharitchan P, Swasdikul D. A Predictive Model for Life-Threatening Neutropenia and Febrile Neutropenia after the First Course of Chop Chemotherapy in Patients with Aggressive Non-Hodgkin's Lymphoma. *Leuk Lymphoma*. 2000; 37(3-4):351-60.
 19. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study. *J Clin Oncol*. 2004; 22(21):4302-11.
 20. Morrison VA, Picozzi V, Scott S, Pohlman B, Dickman E, Lee M, et al. The Impact of Age on Delivered Dose Intensity and Hospitalizations for Febrile Neutropenia in Patients with Intermediate-Grade Non-Hodgkin's Lymphoma Receiving Initial Chop Chemotherapy: A Risk Factor Analysis. *Clin Lymphoma*. 2001; 2(1):47-56.
 21. Morrison VA, Caggiano V, Fridman M, Delgado DJ. A Model to Predict Chemotherapy-Related Severe or Febrile Neutropenia in Cycle One among Breast Cancer and Lymphoma Patients. *J Clin Oncol (Meeting Abstracts)*. 2004; 22(14_suppl):8068-9.
 22. Ray-Coquard I, Borg C, Bachelot T, Sebban C, Philip I, Clapisson G, et al. Baseline and Early Lymphopenia Predict for the Risk of Febrile Neutropenia after Chemotherapy. *Br J Cancer*. 2003; 88(2):181-6.
 23. Blay J, Chauvin F, Cesne AL, Anglaret B, Bouhour D, Lasset C, et al. Early Lymphopenia after Cytotoxic Chemotherapy as a Risk Factor for Febrile Neutropenia. *J Clin Oncol*. 1996; 14:636-43.
 24. Rolston KVI, Rubenstein EB. *Textbook of Febrile Neutropenia*. first ed. London: Martin Dunitz; 2001
 25. Robison LL, Nesbit ME, Jr., Sather HN, Level C, Shahidi N, Kennedy A, et al. Down Syndrome and Acute Leukemia in Children: A 10-Year

- Retrospective Survey from Childrens Cancer Study Group. *J Pediatr.* 1984; 105(2):235-42.
26. Nespoli L, Burgio GR, Ugazio AG, Maccario R. Immunological Features of Down's Syndrome: A Review. *J Intellect Disabil Res.* 1993; 37 (Pt 6):543-51.
 27. de Hingh YC, van der Vossen PW, Gemen EF, Mulder AB, Hop WC, Brus F, et al. Intrinsic Abnormalities of Lymphocyte Counts in Children with Down Syndrome. *J Pediatr.* 2005; 147(6):744-7.
 28. Matondang CS, Kurniati N. Infeksi Hiv Pada Bayi Dan Anak. In: Akib AA, Munasir Z, Kurniati N, editors. *Alergi-Imunologi Anak.* Jakarta: Ikatan Dokter Anak Indonesia; 2008. h. 378-413.
 29. WHO. *Antiretroviral Therapy of Hiv Infection in Infants and Children in Resource-Limited Setting: Toward Universal Access.* Switzerland: WHO; 2006
 30. Witko-Sarsat V, Rieu P, Descamps-Latscha B, Lesavre P, Halbwachs-Mecarelli L. Neutrophils: Molecules, Functions and Pathophysiological Aspects. *Lab Invest.* 2000; 80(5):617-53.
 31. Oski FA. Neutropenia in Children. *Pediatric in Review.* 1981; (3):108-12.
 32. Segel GB, Halterman JS. Neutropenia in Pediatric Practice. *Pediatr Rev.* 2008; 29(1):12-23; quiz 4.
 33. Sharma A, Lokeshwar N. Febrile Neutropenia in Haematological Malignancies. *J Postgrad Med.* 2005; 51 Suppl 1:S42-8.
 34. Donowitz GR MD, Cnrich CJ, Pappas PG, Rolston KV. Infection in the Neutropenic Patient-New Views of an Old Problem. *American Society of Hematology.* 2001; (113-33).
 35. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients. *J Clin Oncol.* 2000; 18(16):3038-51.
 36. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer. *Clin Infect Dis.* 2002; 34(6):730-51.
 37. Dalal S, Zhukovsky DS. Pathophysiology and Management of Fever. *J Support Oncol.* 2006; 4(1):9-16.
 38. Donowitz GR, Maki DG, Cnrich CJ, Pappas PG, Rolston KV. Infections in the Neutropenic Patient--New Views of an Old Problem. *Hematology Am Soc Hematol Educ Program.* 2001:113-39.
 39. Colgan R, Michocki R, Greisman L, Moore TA. Antiviral Drugs in the Immunocompetent Host: Part I. Treatment of Hepatitis, Cytomegalovirus, and Herpes Infections. *Am Fam Physician.* 2003; 67(4):757-62, 675.
 40. Hutter JJ. Childhood Leukemia. *Pediatr Rev.* 2010; 31(6):234-41.
 41. Crawford J, Dale DC, Lyman GH. Chemotherapy-Induced Neutropenia: Risks, Consequences, and New Directions for Its Management. *Cancer.* 2004; 100(2):228-37.

42. O'Grady NP, Alexander M, Dellinger P, Gerberding JL, Heard SO, Maki DG, et al. Guidelines for the Prevention of Intravascular Catheter-Related Infections. *Morbidity and Mortality Weekly Report*. 2002; 51(RR10):1-26.
43. Lee WL, Chen HL, Tsai TY, Lai IC, Chang WC, Huang CH, et al. Risk Factors for Peripheral Intravenous Catheter Infection in Hospitalized Patients: A Prospective Study of 3165 Patients. *Am J Infect Control*. 2009; 37(8):683-6.
44. Haddad FG, Waked CH, Zein EF. Peripheral Venous Catheter-Related Inflammation. A Randomized Prospective Trial. *J Med Liban*. 2006; 54(3):139-45.
45. Rickard CM, McCann D, Munnings J, McGrail MR. Routine Resite of Peripheral Intravenous Devices Every 3 Days Did Not Reduce Complications Compared with Clinically Indicated Resite: A Randomised Controlled Trial. *BMC Med*. 2010; 8:53.
46. Safdar N, Maki DG. Risk of Catheter-Related Bloodstream Infection with Peripherally Inserted Central Venous Catheters Used in Hospitalized Patients. *Chest*. 2005; 128(2):489-95.
47. Foster L, Wallis M, Paterson B, James H. A Descriptive Study of Peripheral Intravenous Catheters in Patients Admitted to a Pediatric Unit in One Australian Hospital. *J Infus Nurs*. 2002; 25(3):159-67.
48. Penack O, Rempf P, Eisenblatter M, Stroux A, Wagner J, Thiel E, et al. Bloodstream Infections in Neutropenic Patients: Early Detection of Pathogens and Directed Antimicrobial Therapy Due to Surveillance Blood Cultures. *Ann Oncol*. 2007; 18(11):1870-4.
49. Shukla NK, Das DK, Deo SV, Raina V. An Analysis of Long-Term Venous Access Catheters in Cancer Patients: Experience from a Tertiary Care Centre in India. *J Postgrad Med*. 2002; 48(1):21-4.
50. Tajmir-Riahi. An Overview of Drug Binding to Human Serum Albumin: Protein Folding and Unfolding. *Scientia Iranica*. 2007; 14(2):87-95.
51. Evans TW. Review Article: Albumin as a Drug--Biological Effects of Albumin Unrelated to Oncotic Pressure. *Aliment Pharmacol Ther*. 2002; 16 Suppl 5:6-11.
52. Sala A, Pencharz P, Barr RD. Children, Cancer, and Nutrition--a Dynamic Triangle in Review. *Cancer*. 2004; 100(4):677-87.
53. Hughes WT, Price RA, Sisko F, Havron WS, Kafatos AG, Schonland M, et al. Protein-Calorie Malnutrition. A Host Determinant for *Pneumocystis Carinii* Infection. *Am J Dis Child*. 1974; 128(1):44-52.
54. Jackson DV, Jr., Nichols AP, Bender RA. Interaction of Albumin and Vincristine with a Human Lymphoblastic Leukemia Cell Line in Vitro. *Cancer Biochem Biophys*. 1980; 4(3):133-6.
55. Imataki O, Ohnishi H, Kitanaka A, Kubota Y, Ishida T, Tanaka T. Pancytopenia Complicated with Peripheral Neuropathy Due to Copper Deficiency: Clinical Diagnostic Review. *Intern Med*. 2008; 47(23):2063-5.
56. Yogyakarta DSD. Kriteria Untuk Menentukan Keluarga / Rumah Tangga Miskin. Yogyakarta: Dinas Sosial DIY Yogyakarta; 2010 [diakses 4

- 2010]; Diunduh dari: <http://www.dinsos.pemda-diy.go.id/index.php?option=content&task=view&id=118&Itemid=46>.
57. Fleiss JL, Levin BA, Paik MC. *Statistical Methods for Rates and Proportions*. 3rd ed. Hoboken, N.J.: Wiley-Interscience; 2003
 58. Waluyo B. *Upah Minimum Regional Propinsi Jawa Tengah, Non Sektor Pada Tahun 2011*. Semarang: Pemerintah Kota Semarang; 2011 [updated 11 Januari 2011; diakses 12/8 2011]; Diunduh dari: http://www.hrcentro.com/umr/jawa_tengah/kota_semarang/non_sektor/2011.
 59. Al-Ahwal MS, Al-Sayws F, Johar I. Febrile Neutropenia Comparison between Solid Tumours and Hematological Malignancies. *Saudi Med J*. 2005;4-7.
 60. Conter V, Rizzari C, Sala A, Chiesa R, Citterio M, A B. Acute Lymphoblastic Leukemia. *Orphanet Encyclopedia*. 2004; 12(1-13).
 61. Linker C, Damon L, Ries C, Navarro W. Intensified and Shortened Cyclical Chemotherapy for Adult Acute Lymphoblastic Leukemia. *J Clin Oncol*. 2002; 20(10):2464-71.
 62. Tanumihardjo SA, Anderson C, Kaufer-Horwitz M, Bode L, Emenaker NJ, Haqq AM, et al. Poverty, Obesity, and Malnutrition: An International Perspective Recognizing the Paradox. *J Am Diet Assoc*. 2007; 107(11):1966-72.
 63. Susilowati D, Karyadi D. Malnutrition and Poverty Alleviation: Review Article. *Asia Pacific J Clin Nutr*. 2002; 11(Suppl):S323-S30.
 64. Drenick EJ, Alvarez LC. Neutropenia in Prolonged Fasting. *Am J Clin Nutr*. 1971; 24(7):859-63.
 65. Basu SK, Fernandez ID, Fisher SG, Asselin BL, Lyman GH. Length of Stay and Mortality Associated with Febrile Neutropenia among Children with Cancer. *J Clin Oncol*. 2005; 23(31):7958-66.
 66. Junqueira BL, Connolly B, Abla O, Tomlinson G, Amaral JG. Severe Neutropenia at Time of Port Insertion Is Not a Risk Factor for Catheter-Associated Infections in Children with Acute Lymphoblastic Leukemia. *Cancer*. 2010; 116(18):4368-75.